¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È CAGR 7.1%¸¦ ±â·ÏÇϸç 2030³â±îÁö 76¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È CAGRÀº 6.7%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÓ»ó ¹Ì»ý¹°ÇÐÀº ÀÓ»ó °Ëü ó¸® ¹× °á°ú ÇØ¼®À» À§ÇØ ±â¼úÀûÀÌ°í ¼÷·ÃµÈ Àη¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó Á÷¿øµéÀº °Ë»ç ó¸® ½Ã°£(TAT)ÀÌ Âª´Ù´Â ÀÌÀ¯·Î ºÒ¸¸À» Åä·ÎÇØ ¿Ô½À´Ï´Ù. ±×·¯³ª ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ¸¹Àº °Ë»ç Àåºñ¿Í ÀåÄ¡°¡ ÀÚµ¿È µÈ ÀåÄ¡·Î ´ëüµÇ¾î ÀÎÀû ¿À·ù¿Í ¼÷·ÃµÈ Àη¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÃÖ¼ÒÈÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ÀÚµ¿È´Â TAT ´ÜÃà, Àη ¹× ½ÇÇè½Ç °ø°£ »ç¿ë °¨¼Ò µîÀÇ ÀÌÁ¡À» Á¦°øÇÏ¿© ÀÌ·¯ÇÑ °Ë»ç¿Í °ü·ÃµÈ Àü¹ÝÀûÀÎ ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. °¢ Á¦Á¶¾÷ü´Â ÀÚµ¿ °Ëü ó¸®, Ç÷¹ÀÌÆ® ÆÇµ¶ ¹× »ý¹° ½Äº°À» µµÀÔÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, GE Healthcare, PerkinElmer ¹× Thermo Fisher´Â Áø´Ü ¾÷°è¿¡¼ ÀÚµ¿È ½Ã½ºÅÛÀ» Á¦°øÇÏ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù.
º´¿ø ³» °¨¿°(HAI) Áõ°¡´Â Áø´Ü ¹× ¸ð´ÏÅ͸µÀ» À§ÇÑ ÀÓ»ó ¹Ì»ý¹°Çп¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °í¼Òµæ ±¹°¡µéÀÌ º´¿ø ³» °¨¿° ´ëÃ¥À» °ÈÇÏ´Â °¡¿îµ¥, ÁßÀú¼Òµæ ±¹°¡µéµµ ÀÌ À§ÇùÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È ½Ã½ºÅÛ°ú Çõ½ÅÀûÀÎ µðÀÚÀÎÀÇ µµÀÔÀº ½ÃÀå °æÀïÀ» °ÈÇÏ°í ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¿ªÇÐÀ» º¯È½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°èº¸°Ç±â±¸(WHO)´Â ¿¡Æ¼¿ÀÇǾÆ, ºÎ¸£Å°³ªÆÄ¼Ò, ³ªÀÌÁö¸®¾Æ, ¾ËÁ¦¸®, ¼¼³×°¥ µî HAI ¹ß»ý·üÀÌ 2.5%-14.8%ÀÎ ±¹°¡¿¡¼ ƯÈ÷ Àû±ØÀûÀ¸·Î Ȱµ¿Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ÀÌµé ±¹°¡¿¡¼´Â HAI Áø´Ü¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àεµ, ½º¸®¶ûÄ«, ÆÄŰ½ºÅº, ºÎź µîÀÇ ±¹°¡µéµµ HAI ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥¿¡ Àû±ØÀûÀ¸·Î Âü¿©Çϰí ÀÖ½À´Ï´Ù. Àεµ¿Í Áß±¹Àº ÇâÈÄ HAI Áø´Ü±â±â ¹× °Ë»ç ¼ö¿ä¸¦ ÁÖµµÇÏ´Â ÁÖ¿ä ±¹°¡°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ¿¹Ãø ±â°£ µ¿¾È ºÐÀÚ Áø´Ü ±â±â ºÐ¾ß°¡ °¡Àå ºü¸¥ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ¾Ï°ú °¨¿°¼º ÁúȯÀÇ Á¶±â ¹ß°ß¿¡ ÀÖ¾î ºÐÀÚ Áø´ÜÀÇ Á߿伺ÀÌ ³ô¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù.
- ½Ã¾àÀº ½Ã¾àÀÇ ¹Ýº¹ ±¸¸Å·Î ÀÎÇØ 2022³â¿¡ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- 2022³â¿¡´Â ºÏ¹Ì°¡ ¼¼°è ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °¨¿°¼º Áúȯ Ä¡·á¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸¿Í Á¤ºÎ ÀÇ·á ±â°üÀÇ º¸Á¶±Ý Áö¿øÀº ÀÌ Áö¿ªÀÇ °·ÂÇÑ »ýÅÂ°è ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
- ¾ÆÅÂÁö¿ªÀº Àεµ, Áß±¹, ÀϺ»ÀÇ ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·Î ÀÎÇØ °áÇÙ, ÄÝ·¹¶ó, ÀåÆ¼Çª½º µî ÀçÃâÇöÇÏ´Â °¨¿°¼º ÁúȯÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ÀÓ»ó ¹Ì»ý¹°ÇÐ : Á¦Ç°º° ÃßÁ¤¡¤µ¿Ç⠺м®
- ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ½ÇÇè½Ç¿ë ±â±¸
- ÀÎÅ¥º£ÀÌÅÍ
- ±×·¥ ¿°»ö±â
- ¹ÚÅ׸®¾Æ ÄÝ·Î´Ï Ä«¿îÅÍ
- ¿ÀÅäŬ·¹ÀÌºê ¸ê±Õ±â
- ÆäÆ®¸® Á¢½Ã ÇÊ·¯
- ÀÚµ¿È ¹è¾ç
- ¹Ì»ý¹° ºÐ¼® Àåºñ
- ºÐÀÚÁø´Ü ±â±â
- Çö¹Ì°æ
- Áú·® ºÐ¼®°è
- ½Ã¾à
Á¦5Àå ÀÓ»ó ¹Ì»ý¹°ÇÐ : Áúȯº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- È£Èí±âÁúȯ
- Ç÷·ù°¨¿°
- ¼Òȱâ Áúȯ
- ¼º°¨¿°Áõ
- ¿ä·Î°¨¿°
- Ä¡ÁÖÁúȯ
- ±âŸ º´
Á¦6Àå ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° Àü¸Á
- Áö¿ªº° ÀÓ»ó ¹Ì»ý¹°ÇÐ ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- ºÏ¹Ì
- ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- ű¹
- Çѱ¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦7Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ½ÃÀå ÁøÃâ±â¾÷ ºÐ·ù
- BIOMERIEUX
- Cepheid.
- Danaher Corporation
- Bruker Corporation
- BD
- Hologic, Inc.
- F. Hoffmann-La Roche Ltd
- Alere, Inc.
LSH 23.10.31
Clinical Microbiology Market Growth & Trends:
The global clinical microbiology market size is expected to reach USD 7.6 billion by 2030, registering a CAGR of 7.1% during the forecast period, according to a new report by Grand View Research, Inc.. It is projected to expand at a CAGR of 6.7% over the forecast period. Clinical microbiology depends on technical and skilled workforce to process and interpret results of clinical specimens. Clinical staff have been complaining about poor Turnaround Time (TAT) of tests. However, with technological advancements, a number of laboratory instruments and equipment are being replaced with automated devices to minimize human error and dependency on skilled workforce.
In addition, automation has benefits such as reduced TAT and use of labor and lab space, thereby reducing overall cost associated with these tests. Manufacturers are focusing on introduction of automatic specimen processing, plate reading, and organism identification. GE Healthcare, PerkinElmer, and Thermo Fisher are some of the key players offering automated systems in the diagnostics industry.
Rising cases of hospital-acquired infections (HAI) is also fueling demand for clinical microbiology for diagnosis and monitoring. As high-income countries are stepping up their pursuit of countering hospital-acquired infections, middle- and low-income countries are recognizing the threat. Introduction of automated systems and innovative designs is expected to intensify market competition and change market dynamics over the forecast period.
The World Health Organization (WHO) is particularly active in countries such as Ethiopia, Burkina Faso, Nigeria, Algeria, and Senegal, where occurrence of HAIs ranged between 2.5% and 14.8%. This has led to increased demand for HAI diagnostics in these countries. Countries such as India, Sri Lanka, Pakistan, and Bhutan are also actively participating in HAI awareness programs. India and China are projected to be the main countries driving demand for HAI diagnostics instruments and tests in future.
Clinical Microbiology Market Report Highlights:
- The molecular diagnostic instruments segment is expected to exhibit the fastest growth rate over the forecast period. This growth can be attributed to the increasing significance of molecular diagnosis in the early detection of cancer and infectious diseases.
- Reagents captured the largest revenue share in 2022 owing to repeat purchase of reagents
- In 2022, North America dominated the global market. Continuous research on infectious disease treatment and subsequent grants from government healthcare agencies are contributing to development of a strong ecosystem in the region
- Asia Pacific is expected to emerge as the fastest growing region during the forecast period owing to rising geriatric population in India, China, and Japan. This has resulted in high prevalence of re-emerging infectious diseases such as tuberculosis, cholera, and typhoid
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product
- 1.1.2. Disease
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Disease outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Clinical Microbiology Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Clinical Microbiology Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Clinical Microbiology : Product Estimates & Trend Analysis
- 4.1. Clinical Microbiology Market: Key Takeaways
- 4.2. Clinical Microbiology Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Laboratory Instruments
- 4.3.1. Laboratory instruments market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.2. Incubators
- 4.3.2.1. Incubators market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.3. Gram stainers
- 4.3.3.1. Gram stainers market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.4. Bacterial colony counters
- 4.3.4.1. Bacterial colony counters market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.5. Autoclave sterilizers
- 4.3.5.1. Autoclave sterilizers market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.6. Petri dish fillers
- 4.3.6.1. Petri dish fillers market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Automated Culture
- 4.4.1. Automated culture market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.2. Microbiology analyzers
- 4.4.2.1. Microbiology analyzers market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.3. Molecular diagnostic instruments
- 4.4.3.1. Molecular diagnostic instruments market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.4. Microscopes
- 4.4.4.1. Microscopes market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.5. Mass spectrometers
- 4.4.5.1. Mass spectrometers market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Reagents
- 4.5.1. Reagents market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Clinical Microbiology: Disease Estimates & Trend Analysis
- 5.1. Clinical Microbiology Market: Key Takeaways
- 5.2. Clinical Microbiology Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Respiratory Diseases
- 5.3.1. Respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Bloodstream Infections
- 5.4.1. Bloodstream infections market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Gastrointestinal Diseases
- 5.5.1. Gastrointestinal diseases market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Sexually Transmitted Diseases
- 5.6.1. Sexually transmitted diseases market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Urinary Tract Infections
- 5.7.1. Urinary tract infections market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.8. Periodontal Diseases
- 5.8.1. Periodontal diseases market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.9. Other Diseases
- 5.9.1. Other diseases market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Clinical Microbiology Market: Regional Estimates & Trend Analysis
- 6.1. Regional Outlook
- 6.2. Clinical Microbiology Market by Region: Key Takeaways
- 6.3. North America
- 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.2. U.S.
- 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.3. Canada
- 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.2. Germany
- 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.3. France
- 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.4. Italy
- 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.5. Spain
- 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.6. Denmark
- 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.7. Sweden
- 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.8. Norway
- 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.2. China
- 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.3. India
- 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.4. Australia
- 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.5. Thailand
- 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.6. South Korea
- 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7. MEA
- 6.7.1. South Africa
- 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.2. Saudi Arabia
- 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.3. UAE
- 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Market Participant Categorization
- 7.2.1. BIOMERIEUX
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. Cepheid.
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. Danaher Corporation
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Bruker Corporation
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. BD
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. Hologic, Inc.
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. F. Hoffmann-La Roche Ltd
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. Alere, Inc.
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives